Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi-database, non-interventional post-authorization safety study

Keyphrases

• Type 2 Diabetic Patients 100%
• Multi-database 100%
• Cardiovascular Safety 100%
• Non-interventional 100%
• Vildagliptin 100%
• Post-authorisation Studies 100%
• Antidiabetic Drugs 83%
• Non-insulin 83%
• Incidence Rate 50%
• Congestive Heart Failure 50%
• Confidence Interval 33%
• Myocardial Infarction 33%
• Acute Coronary Syndrome 33%
• Drug Treatment 16%
• Negative Binomial Regression 16%
• Adverse Cardiovascular Events 16%
• Cardiovascular Outcomes 16%
• Follow-up Time 16%
• Electronic Health Record Databases 16%

Medicine and Dentistry

• Cardiovascular System 100%
• Patient with Type 2 Diabetes 100%
• Vildagliptin 100%
• Antidiabetic Agent 83%
• Congestive Heart Failure 50%
• Apoplexy 33%
• Myocardial Infarction 33%
• Acute Coronary Syndrome 33%
• Drug Therapy 16%
• Cohort Analysis 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Vildagliptin 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Antidiabetic Agent 83%
• Congestive Heart Failure 50%
• Heart Infarction 33%
• Acute Coronary Syndrome 33%
• Cerebrovascular Accident 33%
• Cohort Study 16%
• Pharmacotherapy 16%